Barbara Castelnuovo

Summary

Country: Uganda

Publications

  1. ncbi request reprint Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
    Moses R Kamya
    Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 46:187-93. 2007
  2. pmc Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    Afr Health Sci 8:133-4. 2008
  3. pmc Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings
    Barbara Castelnuovo
    Infectious Diseases Institute, Makerere University, Mulago Hospital Complex, P O Box 22418, Kampala, Uganda
    AIDS Res Treat 2011:736938. 2011
  4. pmc Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda
    Steven J Reynolds
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    BMC Infect Dis 12:381. 2012
  5. pmc Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa
    Barbara Castelnuovo
    Infectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda
    PLoS ONE 7:e51631. 2012
  6. pmc Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
    Joseph B Babigumira
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    BMC Health Serv Res 9:192. 2009
  7. pmc A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa
    B Castelnuovo
    Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda
    Afr Health Sci 10:320-4. 2010
  8. doi request reprint Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda
    Barbara Castelnuovo
    Research Department, Infectious Diseases Institute, Makerere University, Kampala Uganda
    J Acquir Immune Defic Syndr 56:59-63. 2011
  9. doi request reprint Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    Clin Infect Dis 49:965-72. 2009
  10. doi request reprint Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, Uganda
    B Castelnuovo
    Infectious Diseases Institute, PO Box 22418 Mulago Hill, Kampala, Uganda
    Int J STD AIDS 20:123-4. 2009

Detail Information

Publications30

  1. ncbi request reprint Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
    Moses R Kamya
    Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 46:187-93. 2007
    ..We identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART)...
  2. pmc Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    Afr Health Sci 8:133-4. 2008
    ..In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative...
  3. pmc Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings
    Barbara Castelnuovo
    Infectious Diseases Institute, Makerere University, Mulago Hospital Complex, P O Box 22418, Kampala, Uganda
    AIDS Res Treat 2011:736938. 2011
    ..1% with high viremia eventually needed to be switched to second line (P = .008). Conclusions. The use of at least one repeat measurement rather than a single VL measurement could avert from 60% to 80% of unnecessary switches...
  4. pmc Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda
    Steven J Reynolds
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    BMC Infect Dis 12:381. 2012
    ..We compared the genotypic resistance patterns between clients with VLM versus immunological monitoring (IM)...
  5. pmc Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa
    Barbara Castelnuovo
    Infectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda
    PLoS ONE 7:e51631. 2012
    ..The objective of this study was to compare the rate of errors in the database before and after the introduction of the provider-based EMR...
  6. pmc Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
    Joseph B Babigumira
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    BMC Health Serv Res 9:192. 2009
    ..We estimated the potential impact of task-shifting on costs of antiretroviral therapy (ART) and physician supply in Uganda. The study was performed at the Infectious Diseases Institute (IDI) clinic, a large urban HIV clinic...
  7. pmc A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa
    B Castelnuovo
    Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda
    Afr Health Sci 10:320-4. 2010
    ..The aim of this study is to assess anti TB treatment compliance and the factors predictive for poor adherence in Sub-Saharan Africa in the last 10 years...
  8. doi request reprint Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda
    Barbara Castelnuovo
    Research Department, Infectious Diseases Institute, Makerere University, Kampala Uganda
    J Acquir Immune Defic Syndr 56:59-63. 2011
    ..In resource-limited settings, there are only a few antiretroviral treatment (ART) options. Our objective was to evaluate the reasons for first-line ART changes in resource-limited settings...
  9. doi request reprint Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    Clin Infect Dis 49:965-72. 2009
    ....
  10. doi request reprint Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, Uganda
    B Castelnuovo
    Infectious Diseases Institute, PO Box 22418 Mulago Hill, Kampala, Uganda
    Int J STD AIDS 20:123-4. 2009
    ..A similar methodology could be used by other health services to evaluate and compare different models of care...
  11. doi request reprint Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    J Int Assoc Physicians AIDS Care (Chic) 8:52-9. 2009
    ..To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen...
  12. pmc Sexual behaviors over a 3-year period among individuals with advanced HIV/AIDS receiving antiretroviral therapy in an urban HIV clinic in Kampala, Uganda
    Bonnie Wandera
    Infectious Diseases Institute, Kampala, Uganda
    J Acquir Immune Defic Syndr 57:62-8. 2011
    ..Few studies have prospectively examined sexual behaviors of HIV-infected person on antiretroviral therapy (ART) in sub-Saharan Africa...
  13. ncbi request reprint Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda)
    Patricia Mwebaze Songa
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    Clin Infect Dis 45:514-7. 2007
    ..The median serum lactate level was 6.6 mmol/L. All patients had their antiretroviral treatment regimen discontinued. Hospital admission was required for 5 patients. Five patients died...
  14. ncbi request reprint Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    AIDS 22:269-73. 2008
    ..A pruritic papular eruption (PPE) is a common skin manifestation observed in 12-46% of persons with HIV infection living in tropical countries...
  15. pmc Regional differences in predictive accuracy of WHO immunologic failure criteria
    Agnes N Kiragga
    College of Health Sciences, Infectious Diseases Institute, Uganda
    AIDS 26:768-70. 2012
    ..Population-specific guidelines should be developed using large African cohorts to identify more specific and sensitive criteria...
  16. pmc Among patients with sustained viral suppression in a resource-limited setting, CD4 gains are continuous although gender-based differences occur
    Joseph B Sempa
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    PLoS ONE 8:e73190. 2013
    ..We sought to investigate long-term patterns of immune recovery in Ugandan patients on ART with sustained viral suppression...
  17. pmc Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda
    Sabine M Hermans
    Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
    J Acquir Immune Defic Syndr 60:e29-35. 2012
    ..In December 2008, a separate outdoor-integrated TB/HIV clinic was instituted for attendees of a large urban HIV clinic in Uganda. We sought to evaluate associated TB and HIV treatment outcomes...
  18. pmc Low prevalence of Plasmodium falciparum antigenaemia among asymptomatic HAART-treated adults in an urban cohort in Uganda
    Damalie Nakanjako
    Department of Medicine, Makerere University School of Medicine, Kampala, Uganda
    Malar J 10:66. 2011
    ..There is need to evaluate the use of RDTs among highly active anti-retroviral therapy (HAART)-treated people living with HIV (PLHIV)...
  19. pmc Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings
    David B Meya
    Infectious Disease Institute, Makerere University, Mulago Hospital Complex, Kampala, Uganda
    Clin Infect Dis 51:448-55. 2010
    ..We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy...
  20. ncbi request reprint Are the best antiretrovirals being used in Africa?
    Laurence John
    Infectious Disease Institute, Mulago Hospital Complex, Kampala, Uganda
    J HIV Ther 11:11-5. 2006
  21. pmc Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda
    Joseph Sempa
    Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
    BMC Public Health 12:736. 2012
    ..This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/μl (early) versus <250 cell/μl (delayed)...
  22. ncbi request reprint Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
    Hasan M Shihab
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    J Infect Dev Ctries 3:405-7. 2009
    ..The lack of an alternate explanation led us to suspect that Lopinavir/Ritonavir was potentially responsible for the edema...
  23. ncbi request reprint Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda
    Jane Wanyama
    Infectious Disease Institute, Kampala, Uganda
    AIDS 21:1486-7. 2007
    ....
  24. doi request reprint A randomized controlled trial to evaluate the effectiveness of a board game on patients' knowledge uptake of HIV and sexually transmitted diseases at the Infectious Diseases Institute, Kampala, Uganda
    Jane N Wanyama
    Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
    J Acquir Immune Defic Syndr 59:253-8. 2012
    ..The object of this study was to assess the effect of this educational board game on the uptake of knowledge...
  25. pmc Free antiretrovirals must not be restricted only to treatment-naive patients. Experience in Uganda suggests that restricting access is not the way forward
    Robert Colebunders
    Infectious Diseases Institute, Faculty of Medicine, Makerere University, Kampala, Uganda
    PLoS Med 2:e276. 2005
  26. pmc Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis
    Yukari C Manabe
    Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
    PLoS ONE 7:e39187. 2012
    ..We compared the impact of a continuation phase using 6HE or 4HR on total cost and expected mortality from the perspective of the Ugandan national health system...
  27. pmc Quality of data collection in a large HIV observational clinic database in sub-Saharan Africa: implications for clinical research and audit of care
    Agnes N Kiragga
    Research Department, Infectious Diseases Institute, Kampala, Uganda
    J Int AIDS Soc 14:3. 2011
    ..Our objective was to evaluate the completeness and accuracy of recording of key data HIV items in a large routine observational HIV clinic database...
  28. pmc Comparison of methods for correction of mortality estimates for loss to follow-up after ART initiation: a case of the Infectious Diseases Institute, Uganda
    Agnes N Kiragga
    Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
    PLoS ONE 8:e83524. 2013
    ..The objective of this study was to validate methods used to correct mortality estimates for loss-to-follow-up using a cohort with complete death ascertainment...
  29. pmc Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy
    Yukari C Manabe
    Infectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda
    PLoS ONE 7:e34319. 2012
    ....
  30. pmc Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings
    Agnes N Kiragga
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    J Int AIDS Soc 13:42. 2010
    ..Most patients are currently initiated on zidovudine-containing regimens, which can induce anaemia. We investigated the risk factors for early severe anaemia in the first six months of ART initiation...